Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Inflammation is a critical component of cardiovascular disease (CVD), encompassing coronary artery disease (CAD), cerebrovascular events and heart failure and is the leading cause of mortality worldwide. In recent years, metabolism has been placed centrally in the governance of the immune response. Termed immunometabolism, immune cells adapt cellular metabolic pathways to meet demands of activation and thus function. This rewiring influences not only the bioenergetics of the cell but altered metabolites act as signalling molecules to regulate cellular response. In this review, we focus on the TCA cycle derivative, itaconate, as one such metabolite with promising immunomodulatory and therapeutic potential in inflammatory cardiovascular disease.

More information Original publication

DOI

10.1042/BST20210269

Type

Journal article

Publication Date

2021-11-01T00:00:00+00:00

Volume

49

Pages

2189 - 2198

Total pages

9

Keywords

cardiovascular disease, immunometabolism, inflammation, itaconate, metabolic reprogramming, oxidative stress, Biomarkers, Cardiovascular Diseases, Energy Metabolism, Glycolysis, Humans, Inflammation, Inflammation Mediators, Kelch-Like ECH-Associated Protein 1, NF-E2-Related Factor 2, Succinate Dehydrogenase, Succinates